Humanwell Healthcare (600079.SH): HWH217 tablets approved for clinical trials in (WHO Group 1) pulmonary arterial hypertension.

16:08 06/11/2025

Renfu Medicine (600079.SH) announcement, the company's wholly-owned subsidiary Hubei Bio-Pharmaceutical Industry Technology Research Institute Co.,Ltd.

Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. recently received the "Clinical Trial Approval Notice" for HWH217 tablets issued by the National Medical Products Administration, permitting the company to conduct clinical trials for the treatment of arterial pulmonary hypertension in the WHO Group 1.

Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.

Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.

Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.